Targeting the endocannabinoid/CB1 receptor system for treating obesity in Prader–Willi syndrome

Molecular Metabolism

Volumn 5, Issue 12, 2016, Pages 1187-1199

  Knani, Ibrahim ^a   Earley, Brian J ^b   Udi, Shiran ^a   Nemirovski, Alina ^a   Hadar, Rivka ^a   Gammal, Asaad ^a   Cinar, Resat ^b   Hirsch, Harry J ^c   Pollak, Yehuda ^c   Gross, Itai ^c   Eldar Geva, Talia ^c   Reyes Capo, Daniela P ^d   Han, Joan C ^d,e,f   Haqq, Andrea M ^g   Gross Tsur, Varda ^c   Wevrick, Rachel ^g   Tam, Joseph ^a  

^a HEBREW UNIVERSITY OF JERUSALEM   (Israel)

^b NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM   (United States)

^c SHAARE ZEDEK MEDICAL CENTER   (Israel)

^d EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH AND HUMAN DEVELOPMENT   (United States)

^e LE BONHEUR CHILDREN'S MEDICAL CENTER   (United States)

^f UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

^g UNIVERSITY OF ALBERTA   (Canada)

Author keywords

Endocannabinoids; Magel2; Metabolic syndrome; Peripheral CB1 blockade; PWS

Indexed keywords

2 ARACHIDONOYLGLYCEROL; ALANINE AMINOTRANSFERASE; ANANDAMIDE; ANTIOBESITY AGENT; ARACHIDONIC ACID; ASPARTATE AMINOTRANSFERASE; CANNABINOID 1 RECEPTOR; ENDOCANNABINOID; GLUCOSE; HIGH DENSITY LIPOPROTEIN; IBIPINABANT; INSULIN; JD 5037; TRIACYLGLYCEROL; UNCLASSIFIED DRUG; ACYLGLYCEROL; ARACHIDONIC ACID DERIVATIVE; GLYCERYL 2-ARACHIDONATE; JD5037; MAGEL2 PROTEIN, MOUSE; PROTEIN; PYRAZOLE DERIVATIVE; SULFONAMIDE; TUMOR ANTIGEN;

ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BODY COMPOSITION; CARBOHYDRATE OXIDATION; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATIONAL STUDY; DRUG EFFICACY; ENERGY EXPENDITURE; FAT MASS; FAT OXIDATION; FATTY LIVER; FEMALE; GLUCOSE BLOOD LEVEL; GLUCOSE INTOLERANCE; HOMEOSTASIS MODEL ASSESSMENT INSULIN RESISTANCE; HUMAN; HYPERPHAGIA; HYPOTHALAMUS; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; LIVER CELL DAMAGE; LONG TERM CARE; MALE; METABOLIC PARAMETERS; MOLECULARLY TARGETED THERAPY; MOUSE; NONHUMAN; OBESITY; OXIDATION; PHENOTYPE; PHYSICAL ACTIVITY; PRADER WILLI SYNDROME; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SCHOOL CHILD; TREATMENT DURATION; UPREGULATION; WEIGHT GAIN; WEIGHT REDUCTION; ANIMAL; ANTAGONISTS AND INHIBITORS; BLOOD; BODY WEIGHT; BODY WEIGHT LOSS; C57BL MOUSE; CASE CONTROL STUDY; DISEASE MODEL; DRUG EFFECT; GENETICS; METABOLISM;

ADULT; ANIMALS; ANTIGENS, NEOPLASM; ARACHIDONIC ACIDS; BODY WEIGHT; CASE-CONTROL STUDIES; DISEASE MODELS, ANIMAL; ENDOCANNABINOIDS; FEMALE; GLYCERIDES; HUMANS; HYPOTHALAMUS; MALE; MICE; MICE, INBRED C57BL; PRADER-WILLI SYNDROME; PROTEINS; PYRAZOLES; RECEPTOR, CANNABINOID, CB1; SULFONAMIDES; WEIGHT LOSS;

EID: 84997106967     PISSN: None     EISSN: 22128778     Source Type: Journal    
DOI: 10.1016/j.molmet.2016.10.004     Document Type: Article

References (63)

1. [1] Driscoll, D.J., Miller, J.L., Schwartz, S., Cassidy, S.B., Prader–Willi syndrome. Pagon, R.A., Adam, M.P., Ardinger, H.H., Wallace, S.E., Amemiya, A., Bean, L.J.H., et al. (eds.) GeneReviews(R), 1993 [Seattle (WA)].
2. [2] Pacher, P., Batkai, S., Kunos, G., The endocannabinoid system as an emerging target of pharmacotherapy. Pharmacological Reviews 58 (2006), 389–462.
3. [3] Di Marzo, V., Goparaju, S.K., Wang, L., Liu, J., Batkai, S., Jarai, Z., et al. Leptin-regulated endocannabinoids are involved in maintaining food intake. Nature 410 (2001), 822–825.
4. [4] Colombo, G., Agabio, R., Diaz, G., Lobina, C., Reali, R., Gessa, G.L., Appetite suppression and weight loss after the cannabinoid antagonist SR 141716. Life Sciences 63 (1998), PL113–117.
5. [5] Simiand, J., Keane, M., Keane, P.E., Soubrie, P., SR 141716, a CB1 cannabinoid receptor antagonist, selectively reduces sweet food intake in marmoset. Behavioural Pharmacology 9 (1998), 179–181.
6. [6] Williams, C.M., Kirkham, T.C., Anandamide induces overeating: mediation by central cannabinoid (CB1) receptors. Psychopharmacology (Berl) 143 (1999), 315–317.
7. [7] Ravinet Trillou, C., Arnone, M., Delgorge, C., Gonalons, N., Keane, P., Maffrand, J.P., et al. Anti-obesity effect of SR141716, a CB1 receptor antagonist, in diet-induced obese mice. The American Journal of Physiology Regulatory Integrative Comparative Physiology 284 (2003), R345–R353.
8. [8] Despres, J.P., Golay, A., Sjostrom, L., Rimonabant in Obesity-Lipids Study, G. Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia. New England Journal of Medicine 353 (2005), 2121–2134.
9. [9] Pi-Sunyer, F.X., Aronne, L.J., Heshmati, H.M., Devin, J., Rosenstock, J., Group, R.I.-N.A.S., Effect of rimonabant, a cannabinoid-1 receptor blocker, on weight and cardiometabolic risk factors in overweight or obese patients: RIO-North America: a randomized controlled trial. JAMA 295 (2006), 761–775.
10. [10] Scheen, A.J., Finer, N., Hollander, P., Jensen, M.D., Van Gaal, L.F., Efficacy and tolerability of rimonabant in overweight or obese patients with type 2 diabetes: a randomised controlled study. Lancet 368 (2006), 1660–1672.
11. [11] Van Gaal, L.F., Rissanen, A.M., Scheen, A.J., Ziegler, O., Rossner, S., Group, R.I.-E.S., Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study. Lancet 365 (2005), 1389–1397.
12. [12] Motaghedi, R., Lipman, E.G., Hogg, J.E., Christos, P.J., Vogiatzi, M.G., Angulo, M.A., Psychiatric adverse effects of rimonobant in adults with Prader Willi syndrome. The European Journal of Medical Genetics 54 (2011), 14–18.
13. [13] Bensaid, M., Gary-Bobo, M., Esclangon, A., Maffrand, J.P., Le Fur, G., Oury-Donat, F., et al. The cannabinoid CB1 receptor antagonist SR141716 increases Acrp30 mRNA expression in adipose tissue of obese fa/fa rats and in cultured adipocyte cells. Molecular Pharmacology 63 (2003), 908–914.
14. [14] Jourdan, T., Djaouti, L., Demizieux, L., Gresti, J., Verges, B., Degrace, P., CB1 antagonism exerts specific molecular effects on visceral and subcutaneous fat and reverses liver steatosis in diet-induced obese mice. Diabetes 59 (2010), 926–934.
15. [15] Osei-Hyiaman, D., Liu, J., Zhou, L., Godlewski, G., Harvey-White, J., Jeong, W.I., et al. Hepatic CB1 receptor is required for development of diet-induced steatosis, dyslipidemia, and insulin and leptin resistance in mice. The Journal of Clinical Investigation 118 (2008), 3160–3169.
16. [16] Pagotto, U., Marsicano, G., Cota, D., Lutz, B., Pasquali, R., The emerging role of the endocannabinoid system in endocrine regulation and energy balance. Endocrine Reviews 27 (2006), 73–100.
17. [17] Quarta, C., Bellocchio, L., Mancini, G., Mazza, R., Cervino, C., Braulke, L.J., et al. CB(1) signaling in forebrain and sympathetic neurons is a key determinant of endocannabinoid actions on energy balance. Cell Metabolism 11 (2010), 273–285.
18. [18] Di Marzo, V., The endocannabinoid system in obesity and type 2 diabetes. Diabetologia 51 (2008), 1356–1367.
19. [19] Kunos, G., Osei-Hyiaman, D., Liu, J., Godlewski, G., Batkai, S., Endocannabinoids and the control of energy homeostasis. The Journal of Biological Chemistry 283 (2008), 33021–33025.
20. [20] Tam, J., Vemuri, V.K., Liu, J., Batkai, S., Mukhopadhyay, B., Godlewski, G., et al. Peripheral CB1 cannabinoid receptor blockade improves cardiometabolic risk in mouse models of obesity. The Journal of Clinical Investigation 120 (2010), 2953–2966.
21. [21] Tam, J., Cinar, R., Liu, J., Godlewski, G., Wesley, D., Jourdan, T., et al. Peripheral cannabinoid-1 receptor inverse agonism reduces obesity by reversing leptin resistance. Cell Metabolism 16 (2012), 167–179.
22. [22] Bischof, J.M., Stewart, C.L., Wevrick, R., Inactivation of the mouse Magel2 gene results in growth abnormalities similar to Prader–Willi syndrome. Human Molecular Genetics 16 (2007), 2713–2719.
23. [23] Kuczmarski, R.J., Ogden, C.L., Grummer-Strawn, L.M., Flegal, K.M., Guo, S.S., Wei, R., et al. CDC growth charts: United States. Advance Data, 2000, 1–27.
24. [24] Mercer, R.E., Kwolek, E.M., Bischof, J.M., van Eede, M., Henkelman, R.M., Wevrick, R., Regionally reduced brain volume, altered serotonin neurochemistry, and abnormal behavior in mice null for the circadian rhythm output gene Magel2. American Journal of Medical Genetics Neuropsychiatric Genetics 150B (2009), 1085–1099.
25. [25] Tschop, M.H., Speakman, J.R., Arch, J.R., Auwerx, J., Bruning, J.C., Chan, L., et al. A guide to analysis of mouse energy metabolism. Nature Methods 9 (2012), 57–63.
26. [26] Chorvat, R.J., Berbaum, J., Seriacki, K., McElroy, J.F., JD-5006 and JD-5037: peripherally restricted (PR) cannabinoid-1 receptor blockers related to SLV-319 (Ibipinabant) as metabolic disorder therapeutics devoid of CNS liabilities. Bioorganic & Medicinal Chemistry Letters 22 (2012), 6173–6180.
27. [27] Resnick, J.L., Nicholls, R.D., Wevrick, R., Prader-Willi Syndrome Animal Models Working, G. Recommendations for the investigation of animal models of Prader–Willi syndrome. Mammalian Genome 24 (2013), 165–178.
28. [28] Tennese, A.A., Wevrick, R., Impaired hypothalamic regulation of endocrine function and delayed counterregulatory response to hypoglycemia in Magel2-null mice. Endocrinology 152 (2011), 967–978.
29. [29] Lee, S., Kozlov, S., Hernandez, L., Chamberlain, S.J., Brannan, C.I., Stewart, C.L., et al. Expression and imprinting of MAGEL2 suggest a role in Prader–Willi syndrome and the homologous murine imprinting phenotype. Human Molecular Genetics 9 (2000), 1813–1819.
30. [30] Cota, D., Marsicano, G., Tschop, M., Grubler, Y., Flachskamm, C., Schubert, M., et al. The endogenous cannabinoid system affects energy balance via central orexigenic drive and peripheral lipogenesis. The Journal of Clinical Investigation 112 (2003), 423–431.
31. [31] Ravinet Trillou, C., Delgorge, C., Menet, C., Arnone, M., Soubrie, P., CB1 cannabinoid receptor knockout in mice leads to leanness, resistance to diet-induced obesity and enhanced leptin sensitivity. International Journal of Obesity and Related Metabolic Disorders 28 (2004), 640–648.
32. [32] Jung, K.M., Clapper, J.R., Fu, J., D'Agostino, G., Guijarro, A., Thongkham, D., et al. 2-Arachidonoylglycerol signaling in forebrain regulates systemic energy metabolism. Cell Metabolism 15 (2012), 299–310.
33. [33] Jbilo, O., Ravinet-Trillou, C., Arnone, M., Buisson, I., Bribes, E., Peleraux, A., et al. The CB1 receptor antagonist rimonabant reverses the diet-induced obesity phenotype through the regulation of lipolysis and energy balance. FASEB Journal 19 (2005), 1567–1569.
34. [34] Steinberg, B.A., Cannon, C.P., Cannabinoid-1 receptor blockade in cardiometabolic risk reduction: safety, tolerability, and therapeutic potential. American Journal of Cardiology 100 (2007), 27P–32P.
35. [35] Silvestri, C., Di Marzo, V., The endocannabinoid system in energy homeostasis and the etiopathology of metabolic disorders. Cell Metabolism 17 (2013), 475–490.
36. [36] Engeli, S., Peripheral metabolic effects of endocannabinoids and cannabinoid receptor blockade. Obesity Facts 1 (2008), 8–15.
37. [37] Cote, M., Matias, I., Lemieux, I., Petrosino, S., Almeras, N., Despres, J.P., et al. Circulating endocannabinoid levels, abdominal adiposity and related cardiometabolic risk factors in obese men. The International Journal of Obesity (London) 31 (2007), 692–699.
38. [38] Di Marzo, V., Cote, M., Matias, I., Lemieux, I., Arsenault, B.J., Cartier, A., et al. Changes in plasma endocannabinoid levels in viscerally obese men following a 1 year lifestyle modification programme and waist circumference reduction: associations with changes in metabolic risk factors. Diabetologia 52 (2009), 213–217.
39. [39] Blankman, J.L., Simon, G.M., Cravatt, B.F., A comprehensive profile of brain enzymes that hydrolyze the endocannabinoid 2-arachidonoylglycerol. Chemistry & Biology 14 (2007), 1347–1356.
40. [40] Sergeant, S., Hugenschmidt, C.E., Rudock, M.E., Ziegler, J.T., Ivester, P., Ainsworth, H.C., et al. Differences in arachidonic acid levels and fatty acid desaturase (FADS) gene variants in African Americans and European Americans with diabetes or the metabolic syndrome. British Journal of Nutrition 107 (2012), 547–555.
41. [41] Bischof, J.M., Van Der Ploeg, L.H., Colmers, W.F., Wevrick, R., Magel2-null mice are hyper-responsive to setmelanotide, a melanocortin 4 receptor agonist. British Journal of Pharmacology 173 (2016), 2614–2621.
42. [42] Cardinal, P., Bellocchio, L., Clark, S., Cannich, A., Klugmann, M., Lutz, B., et al. Hypothalamic CB1 cannabinoid receptors regulate energy balance in mice. Endocrinology 153 (2012), 4136–4143.
43. [43] Lage, R., Parisi, C., Seoane-Collazo, P., Ferno, J., Mazza, R., Bosch, F., et al. Lack of hypophagia in CB1 null mice is associated to decreased hypothalamic POMC and CART expression. The International Journal of Neuropsychopharmacology, 18, 2015.
44. [44] Koch, M., Varela, L., Kim, J.G., Kim, J.D., Hernandez-Nuno, F., Simonds, S.E., et al. Hypothalamic POMC neurons promote cannabinoid-induced feeding. Nature 519 (2015), 45–50.
45. [45] Kirkham, T.C., Williams, C.M., Fezza, F., Di Marzo, V., Endocannabinoid levels in rat limbic forebrain and hypothalamus in relation to fasting, feeding and satiation: stimulation of eating by 2-arachidonoyl glycerol. British Journal of Pharmacology 136 (2002), 550–557.
46. [46] Cristino, L., Luongo, L., Imperatore, R., Boccella, S., Becker, T., Morello, G., et al. Orexin-A and endocannabinoid activation of the descending antinociceptive pathway underlies altered pain perception in leptin signaling deficiency. Neuropsychopharmacology 41 (2016), 508–520.
47. [47] Cristino, L., Busetto, G., Imperatore, R., Ferrandino, I., Palomba, L., Silvestri, C., et al. Obesity-driven synaptic remodeling affects endocannabinoid control of orexinergic neurons. Proceedings of the National Academy of Sciences of the United States of America 110 (2013), E2229–E2238.
48. [48] Butler, M.G., Nelson, T.A., Driscoll, D.J., Manzardo, A.M., Evaluation of plasma substance P and Beta-endorphin levels in children with Prader–Willi syndrome. The Journal of Rare Disorders, 3, 2015.
49. [49] Uno, K., Katagiri, H., Yamada, T., Ishigaki, Y., Ogihara, T., Imai, J., et al. Neuronal pathway from the liver modulates energy expenditure and systemic insulin sensitivity. Science 312 (2006), 1656–1659.
50. [50] Imai, J., Katagiri, H., Yamada, T., Ishigaki, Y., Suzuki, T., Kudo, H., et al. Regulation of pancreatic beta cell mass by neuronal signals from the liver. Science 322 (2008), 1250–1254.
51. [51] Maccarrone, M., Bab, I., Biro, T., Cabral, G.A., Dey, S.K., Di Marzo, V., et al. Endocannabinoid signaling at the periphery: 50 years after THC. Trends in Pharmacological Sciences 36 (2015), 277–296.
52. [52] Ishac, E.J., Jiang, L., Lake, K.D., Varga, K., Abood, M.E., Kunos, G., Inhibition of exocytotic noradrenaline release by presynaptic cannabinoid CB1 receptors on peripheral sympathetic nerves. British Journal of Pharmacology 118 (1996), 2023–2028.
53. [53] Niederhoffer, N., Schmid, K., Szabo, B., The peripheral sympathetic nervous system is the major target of cannabinoids in eliciting cardiovascular depression. Naunyn-Schmiedeberg's Archives of Pharmacology 367 (2003), 434–443.
54. [54] Coutts, A.A., Pertwee, R.G., Inhibition by cannabinoid receptor agonists of acetylcholine release from the guinea-pig myenteric plexus. British Journal of Pharmacology 121 (1997), 1557–1566.
55. [55] Burdyga, G., Lal, S., Varro, A., Dimaline, R., Thompson, D.G., Dockray, G.J., Expression of cannabinoid CB1 receptors by vagal afferent neurons is inhibited by cholecystokinin. The Journal of Neuroscience 24 (2004), 2708–2715.
56. [56] Hoybye, C., Hilding, A., Jacobsson, H., Thoren, M., Metabolic profile and body composition in adults with Prader–Willi syndrome and severe obesity. The Journal of Clinical Endocrinology and Metabolism 87 (2002), 3590–3597.
57. [57] Goldstone, A.P., Brynes, A.E., Thomas, E.L., Bell, J.D., Frost, G., Holland, A., et al. Resting metabolic rate, plasma leptin concentrations, leptin receptor expression, and adipose tissue measured by whole-body magnetic resonance imaging in women with Prader–Willi syndrome. American Journal of Clinical Nutrition 75 (2002), 468–475.
58. [58] Mercer, R.E., Michaelson, S.D., Chee, M.J., Atallah, T.A., Wevrick, R., Colmers, W.F., Magel2 is required for leptin-mediated depolarization of POMC neurons in the hypothalamic arcuate nucleus in mice. PLOS Genetics, 9, 2013, e1003207.
59. [59] Maillard, J., Park, S., Croizier, S., Vanacker, C., Cook, J.H., Prevot, V., et al. Loss of Magel2 impairs the development of hypothalamic anorexigenic circuits. Human Molecular Genetics, 2016 pii: ddw169.
60. [60] Pravdivyi, I., Ballanyi, K., Colmers, W.F., Wevrick, R., Progressive postnatal decline in leptin sensitivity of arcuate hypothalamic neurons in the Magel2-null mouse model of Prader–Willi syndrome. Human Molecular Genetics 24 (2015), 4276–4283.
61. [61] Minokoshi, Y., Kim, Y.B., Peroni, O.D., Fryer, L.G., Muller, C., Carling, D., et al. Leptin stimulates fatty-acid oxidation by activating AMP-activated protein kinase. Nature 415 (2002), 339–343.
62. [62] Tedesco, L., Valerio, A., Cervino, C., Cardile, A., Pagano, C., Vettor, R., et al. Cannabinoid type 1 receptor blockade promotes mitochondrial biogenesis through endothelial nitric oxide synthase expression in white adipocytes. Diabetes 57 (2008), 2028–2036.
63. [63] Beery, A.K., Zucker, I., Sex bias in neuroscience and biomedical research. Neuroscience & Biobehavioral Reviews 35 (2011), 565–572.